Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**GLAND PHARMA LIMITED – ESG FINANCIAL RISK SUMMARY** Gland Pharma faces critical compliance exposure as its maximum 10.0/10 compliance risk score indicates potential SEBI BRSR Core Expansion non-compliance, with enforcement actions and delisting risk for top-tier listed entities—a material governance threat to market valuation. The company's ₹7–25 crore estimated compliance cost represents 0.17–0.61% of FY revenue, though the wide range suggests incomplete EPR and emissions disclosure framework clarity, creating contingent liability uncertainty. EPR exposure (6.5/10) is a secondary but quantifiable risk; if EPR liabilities apply to pharmaceutical packaging, costs could exceed initial estimates under Extended Producer Responsibility rules without current data transparency. Immediate priority: close the emissions data gap (Scope 1 & 2 reporting "None" is implausible for a manufacturing pharma company) and clarify EPR applicability to avoid regulatory penalties and loss of investor credibility under mandatory BRSR disclosures.
Source: GLAND PHARMA LIMITED BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.